Andere Sprachen Astellas Pharma Inc.

Aktien

856273

JP3942400007

4503

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 25.04.2024			% 5 Tage	% 1. Jan.
1’455 ^JPY	-0.95%		-0.78%	-13.70%

08:00	Astellas Pharma Inc. gibt Rücktritte aus Vorstand und Ausschuss bekannt	CI
24.04.	Astellas Pharma Inc. gibt die Genehmigung der Europäischen Kommission für die Verwendung in zusätzlichen Behandlungssituationen bei rezidivierendem frühem Prostatakrebs bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Astellas Pharma Inc. Announces Board and Committee Retirements	08:00
European Commission Approves Astellas Pharma Label Extension for Xtandi	02:49
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	24.04.
Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM	23.04.
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	22.04.
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	22.04.
Lupin Launches Mirabegron Extended-Release Tablets in US	22.04.
Japan Inc makes a renewed U.S. push as China fears mount	17.04.
Middle East Tensions Blunt Asian Stock Markets Excepting China	15.04.
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	15.04.
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	15.04.
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	15.04.
Astellas Pharma Inc. Provides Impairment Loss for Intangible Assets Guidance for the Fourth Quarter 2023	12.04.
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	12.04.
U.S. FDA Accepts Astellas' Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy	04.04.
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	01.04.
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China	28.03.
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	28.03.
Astellas VYLOY Approved in Japan for Treatment of Gastric Cancer	27.03.
Iveric Bio - Astellas Receives Permanent J-code for IZERVAY for Geographic Atrophy	27.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Astellas Pharma Inc.

Aktien

856273

JP3942400007

4503

Andere Sprachen

Filter